Antibody-dependent enhancement (ADE) is a mechanism by which the pathogenesis of
certain viral infections is enhanced in the presence of sub-neutralizing or cross-reactive non …

Antiretroviral therapy can effectively block HIV-1 replication and prevent or reverse
immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within …

Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike
(S) protein receptor-binding domain and block virus interactions with the cellular receptor …

SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42 million
infections and 1 million deaths since its emergence in December 2019. There are few …

HIV-1 infection remains a public health problem with no cure. Anti-retroviral therapy (ART) is
effective but requires lifelong drug administration owing to a stable reservoir of latent …

Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …

Immunodeficient mice engrafted with functional human cells and tissues, that is, humanized
mice, have become increasingly important as small, preclinical animal models for the study …

Monoclonal antibody 10-1074 targets the V3 glycan supersite on the HIV-1 envelope (Env)
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …

HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was
largely ineffective in pre-clinical and clinical settings and was therefore abandoned …

A latent reservoir for HIV-1 in resting CD4+ T lymphocytes precludes cure. Mechanisms
underlying reservoir stability are unclear. Recent studies suggest an unexpected degree of …